Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Core Insights - Marker Therapeutics, Inc. has reported promising results from a Phase 1/2 clinical study at Baylor College of Medicine, demonstrating a disease control rate of 84.6% in pancreatic cancer patients treated with Multi-Antigen Targeted T cells combined with frontline chemotherapy [2][5]. Group 1: Clinical Study Results - The Phase 1/2 clinical study showed a median duration of response of 7.5 months for patients achieving a partial or complete response, with a median overall survival rate of 14.1 months [2]. - The study indicated a favorable safety profile for Multi-Antigen Targeted T cells when used in combination with chemotherapy, without increasing toxicity [3]. Group 2: Mechanism and Efficacy - The research highlighted a correlation between clinical benefits and the expansion and persistence of infused Multi-Antigen Targeted T cells, which were still present in patients 12 months post-treatment [4]. - Chemotherapy was noted to facilitate T cell infiltration into tumors by breaking down protective stromal cells, enhancing the anti-tumor response [3]. Group 3: Future Developments - Marker Therapeutics plans to enhance the MAR-T cell technology by increasing the number of target antigens and cell doses, and by adding lymphodepletion to support T cell expansion [5]. - The company has secured non-dilutive funding from the NIH and CPRIT to support its pancreatic cancer program, allowing it to advance without affecting its financial runway [6]. Group 4: Product Information - The lead product, MT-601, is a MAR-T cell therapy targeting six tumor antigens and is currently being investigated in the Phase 1 APOLLO trial for lymphoma [9]. - The company aims to explore the application of MT-601 beyond lymphoma to include pancreatic cancer, supported by funding from the National Cancer Institute and CPRIT [9].